| 16-Bromoepiandrosterone | 16-Bromoepiandrosterone may increase the hypokalemic activities of Metolazone. | Investigational |
| 19-norandrostenedione | 19-norandrostenedione may increase the hypokalemic activities of Metolazone. | Experimental, Illicit |
| 2,4-thiazolidinedione | The therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Metolazone. | Investigational |
| 5-androstenedione | 5-androstenedione may increase the hypokalemic activities of Metolazone. | Experimental, Illicit |
| 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline | 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Metolazone. | Experimental |
| Acarbose | The therapeutic efficacy of Acarbose can be decreased when used in combination with Metolazone. | Approved, Investigational |
| Acebutolol | The risk or severity of adverse effects can be increased when Metolazone is combined with Acebutolol. | Approved |
| Aceclofenac | The therapeutic efficacy of Metolazone can be decreased when used in combination with Aceclofenac. | Approved |
| Acetazolamide | The risk or severity of adverse effects can be increased when Metolazone is combined with Acetazolamide. | Approved, Vet Approved |
| Acetohexamide | The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Metolazone. | Withdrawn |
| Acetyldigitoxin | The risk or severity of adverse effects can be increased when Metolazone is combined with Acetyldigitoxin. | Approved |
| Acetylsalicylic acid | The therapeutic efficacy of Metolazone can be decreased when used in combination with Acetylsalicylic acid. | Approved, Vet Approved |
| Aclidinium | The serum concentration of Metolazone can be increased when it is combined with Aclidinium. | Approved |
| Adapalene | The therapeutic efficacy of Metolazone can be decreased when used in combination with Adapalene. | Approved |
| AICA ribonucleotide | The therapeutic efficacy of Aicar can be decreased when used in combination with Metolazone. | Experimental |
| Alclometasone | Alclometasone may increase the hypokalemic activities of Metolazone. | Approved |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metolazone. | Approved |
| Aldosterone | Aldosterone may increase the hypokalemic activities of Metolazone. | Experimental |
| Alfacalcidol | Metolazone may increase the hypercalcemic activities of Alfacalcidol. | Approved, Nutraceutical |
| Alfentanil | The risk or severity of adverse effects can be increased when Alfentanil is combined with Metolazone. | Approved, Illicit |
| Alfuzosin | Alfuzosin may increase the hypotensive activities of Metolazone. | Approved, Investigational |
| Aliskiren | The risk or severity of adverse effects can be increased when Metolazone is combined with Aliskiren. | Approved, Investigational |
| Allopurinol | The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Metolazone. | Approved |
| Alogliptin | The therapeutic efficacy of Alogliptin can be decreased when used in combination with Metolazone. | Approved |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Metolazone. | Experimental, Illicit |
| Alprenolol | Metolazone may increase the hypotensive activities of Alprenolol. | Approved, Withdrawn |
| Ambrisentan | Metolazone may increase the hypotensive activities of Ambrisentan. | Approved, Investigational |
| Amcinonide | Amcinonide may increase the hypokalemic activities of Metolazone. | Approved |
| Amifostine | Metolazone may increase the hypotensive activities of Amifostine. | Approved, Investigational |
| Amiloride | The risk or severity of adverse effects can be increased when Metolazone is combined with Amiloride. | Approved |
| Amiodarone | The risk or severity of adverse effects can be increased when Metolazone is combined with Amiodarone. | Approved, Investigational |
| Amlodipine | The risk or severity of adverse effects can be increased when Amlodipine is combined with Metolazone. | Approved |
| Amobarbital | Amobarbital may increase the orthostatic hypotensive activities of Metolazone. | Approved, Illicit |
| Amphotericin B | The risk or severity of adverse effects can be increased when Metolazone is combined with Amphotericin B. | Approved, Investigational |
| Amyl Nitrite | The risk or severity of adverse effects can be increased when Metolazone is combined with Amyl Nitrite. | Approved |
| Andrographolide | The therapeutic efficacy of Metolazone can be decreased when used in combination with HMPL-004. | Investigational |
| Androstenedione | 4-Androstenedione may increase the hypokalemic activities of Metolazone. | Experimental, Illicit |
| Anecortave | Anecortave may increase the hypokalemic activities of Metolazone. | Investigational |
| Anisodamine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Anisodamine. | Investigational |
| Anisotropine Methylbromide | The serum concentration of Metolazone can be increased when it is combined with Anisotropine Methylbromide. | Approved |
| Antipyrine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Antipyrine. | Approved |
| Apocynin | The therapeutic efficacy of Metolazone can be decreased when used in combination with Acetovanillone. | Investigational |
| Apomorphine | The risk or severity of adverse effects can be increased when Metolazone is combined with Apomorphine. | Approved, Investigational |
| Apraclonidine | The risk or severity of adverse effects can be increased when Metolazone is combined with Apraclonidine. | Approved |
| Apremilast | The therapeutic efficacy of Metolazone can be decreased when used in combination with Apremilast. | Approved, Investigational |
| Arbutamine | Arbutamine may increase the hypokalemic activities of Metolazone. | Approved |
| Arformoterol | Arformoterol may increase the hypokalemic activities of Metolazone. | Approved, Investigational |
| Aripiprazole | Aripiprazole may increase the hypotensive activities of Metolazone. | Approved, Investigational |
| Arotinolol | The risk or severity of adverse effects can be increased when Metolazone is combined with Arotinolol. | Approved |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Metolazone is combined with Arsenic trioxide. | Approved, Investigational |
| Atenolol | The risk or severity of adverse effects can be increased when Atenolol is combined with Metolazone. | Approved |
| Atracurium besylate | The serum concentration of Metolazone can be increased when it is combined with Atracurium besylate. | Approved |
| Atropine | The serum concentration of Metolazone can be increased when it is combined with Atropine. | Approved, Vet Approved |
| Azapropazone | The therapeutic efficacy of Metolazone can be decreased when used in combination with Azapropazone. | Withdrawn |
| Azelastine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Azelastine. | Approved |
| Azilsartan medoxomil | The risk or severity of adverse effects can be increased when Metolazone is combined with Azilsartan medoxomil. | Approved |
| Balaglitazone | The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Metolazone. | Investigational |
| Balsalazide | The therapeutic efficacy of Metolazone can be decreased when used in combination with Balsalazide. | Approved, Investigational |
| Bambuterol | Bambuterol may increase the hypokalemic activities of Metolazone. | Approved |
| Barbexaclone | Barbexaclone may increase the orthostatic hypotensive activities of Metolazone. | Experimental |
| Barbital | Barbital may increase the orthostatic hypotensive activities of Metolazone. | Illicit |
| Barnidipine | The risk or severity of adverse effects can be increased when Metolazone is combined with Barnidipine. | Approved |
| Beclomethasone dipropionate | Beclomethasone dipropionate may increase the hypokalemic activities of Metolazone. | Approved, Investigational |
| Benactyzine | The serum concentration of Metolazone can be increased when it is combined with Benactyzine. | Withdrawn |
| Benazepril | The risk or severity of adverse effects can be increased when Metolazone is combined with Benazepril. | Approved, Investigational |
| Bendroflumethiazide | The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Metolazone. | Approved |
| Benmoxin | Benmoxin may increase the hypotensive activities of Metolazone. | Withdrawn |
| Benoxaprofen | The therapeutic efficacy of Metolazone can be decreased when used in combination with Benoxaprofen. | Withdrawn |
| Benzatropine | The serum concentration of Metolazone can be increased when it is combined with Benzatropine. | Approved |
| Bepridil | Metolazone may increase the hypotensive activities of Bepridil. | Approved, Withdrawn |
| Betamethasone | Betamethasone may increase the hypokalemic activities of Metolazone. | Approved, Vet Approved |
| Betaxolol | The risk or severity of adverse effects can be increased when Betaxolol is combined with Metolazone. | Approved |
| Bethanidine | Bethanidine may increase the hypotensive activities of Metolazone. | Approved |
| Betulinic Acid | The therapeutic efficacy of Metolazone can be decreased when used in combination with Betulinic Acid. | Investigational |
| Bezitramide | The risk or severity of adverse effects can be increased when Bezitramide is combined with Metolazone. | Experimental, Illicit, Withdrawn |
| Bimatoprost | Metolazone may increase the hypotensive activities of Bimatoprost. | Approved, Investigational |
| Biperiden | The serum concentration of Metolazone can be increased when it is combined with Biperiden. | Approved |
| Bisoprolol | The risk or severity of adverse effects can be increased when Metolazone is combined with Bisoprolol. | Approved |
| Bortezomib | The risk or severity of adverse effects can be increased when Metolazone is combined with Bortezomib. | Approved, Investigational |
| Bosentan | Metolazone may increase the hypotensive activities of Bosentan. | Approved, Investigational |
| Bretylium | The risk or severity of adverse effects can be increased when Metolazone is combined with Bretylium. | Approved |
| Brimonidine | The risk or severity of adverse effects can be increased when Brimonidine is combined with Metolazone. | Approved |
| Brimonidine | Brimonidine may increase the antihypertensive activities of Metolazone. | Approved |
| Bromfenac | The therapeutic efficacy of Metolazone can be decreased when used in combination with Bromfenac. | Approved |
| Bromocriptine | The risk or severity of adverse effects can be increased when Metolazone is combined with Bromocriptine. | Approved, Investigational |
| Bucillamine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Bucillamine. | Investigational |
| Budesonide | Budesonide may increase the hypokalemic activities of Metolazone. | Approved |
| Buformin | The therapeutic efficacy of Buformin can be decreased when used in combination with Metolazone. | Withdrawn |
| Bumetanide | The risk or severity of adverse effects can be increased when Metolazone is combined with Bumetanide. | Approved |
| Bupivacaine | The risk or severity of adverse effects can be increased when Metolazone is combined with Bupivacaine. | Approved, Investigational |
| Bupranolol | Metolazone may increase the hypotensive activities of Bupranolol. | Approved |
| Buprenorphine | The risk or severity of adverse effects can be increased when Buprenorphine is combined with Metolazone. | Approved, Illicit, Investigational, Vet Approved |
| Butorphanol | The risk or severity of adverse effects can be increased when Butorphanol is combined with Metolazone. | Approved, Illicit, Vet Approved |
| Calcidiol | Metolazone may increase the hypercalcemic activities of Calcidiol. | Approved, Nutraceutical |
| Calcipotriol | Metolazone may increase the hypercalcemic activities of Calcipotriol. | Approved |
| Calcitriol | Metolazone may increase the hypercalcemic activities of Calcitriol. | Approved, Nutraceutical |
| Calcium | Metolazone may decrease the excretion rate of Calcium which could result in a higher serum level. | Nutraceutical |
| Calcium Acetate | Metolazone may decrease the excretion rate of Calcium Acetate which could result in a higher serum level. | Approved |
| Calcium Carbonate | Metolazone may decrease the excretion rate of Calcium carbonate which could result in a higher serum level. | Approved |
| Calcium Chloride | Metolazone may decrease the excretion rate of Calcium Chloride which could result in a higher serum level. | Approved |
| Calcium Citrate | Metolazone may decrease the excretion rate of Calcium citrate which could result in a higher serum level. | Approved |
| Calcium glubionate | Metolazone may decrease the excretion rate of Calcium glubionate which could result in a higher serum level. | Approved |
| Calcium Gluceptate | Metolazone may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level. | Approved |
| Calcium gluconate | Metolazone may decrease the excretion rate of Calcium gluconate which could result in a higher serum level. | Approved, Vet Approved |
| Canagliflozin | The risk or severity of adverse effects can be increased when Metolazone is combined with Canagliflozin. | Approved |
| Candesartan | The risk or severity of adverse effects can be increased when Metolazone is combined with Candesartan. | Approved |
| Candoxatril | Metolazone may increase the hypotensive activities of Candoxatril. | Experimental |
| Captopril | The risk or severity of adverse effects can be increased when Metolazone is combined with Captopril. | Approved |
| Carbamazepine | The risk or severity of adverse effects can be increased when Metolazone is combined with Carbamazepine. | Approved, Investigational |
| Carbetocin | The risk or severity of adverse effects can be increased when Metolazone is combined with Carbetocin. | Approved |
| Carfentanil | The risk or severity of adverse effects can be increased when Carfentanil is combined with Metolazone. | Illicit, Vet Approved |
| Caroxazone | Caroxazone may increase the hypotensive activities of Metolazone. | Withdrawn |
| Carprofen | The therapeutic efficacy of Metolazone can be decreased when used in combination with Carprofen. | Approved, Vet Approved, Withdrawn |
| Carteolol | The risk or severity of adverse effects can be increased when Carteolol is combined with Metolazone. | Approved |
| Carvedilol | The risk or severity of adverse effects can be increased when Metolazone is combined with Carvedilol. | Approved, Investigational |
| Castanospermine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Castanospermine. | Experimental |
| Celecoxib | The therapeutic efficacy of Metolazone can be decreased when used in combination with Celecoxib. | Approved, Investigational |
| Celiprolol | Celiprolol may increase the hypokalemic activities of Metolazone. | Approved, Investigational |
| Chloroquine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Chloroquine. | Approved, Vet Approved |
| Chlorothiazide | The risk or severity of adverse effects can be increased when Metolazone is combined with Chlorothiazide. | Approved, Vet Approved |
| Chlorphenoxamine | The serum concentration of Metolazone can be increased when it is combined with Chlorphenoxamine. | Withdrawn |
| Chlorpromazine | The risk or severity of adverse effects can be increased when Metolazone is combined with Chlorpromazine. | Approved, Vet Approved |
| Chlorpropamide | The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Metolazone. | Approved |
| Chlorthalidone | The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Metolazone. | Approved |
| Cholecalciferol | Metolazone may increase the hypercalcemic activities of Cholecalciferol. | Approved, Nutraceutical |
| Cholestyramine | Cholestyramine can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Choline magnesium trisalicylate | The therapeutic efficacy of Metolazone can be decreased when used in combination with Trisalicylate-choline. | Approved |
| Ciclesonide | Ciclesonide may increase the hypokalemic activities of Metolazone. | Approved, Investigational |
| Ciglitazone | The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Metolazone. | Experimental |
| Cilazapril | The risk or severity of adverse effects can be increased when Metolazone is combined with Cilazapril. | Approved |
| Cilnidipine | The risk or severity of adverse effects can be increased when Metolazone is combined with Cilnidipine. | Approved |
| Citalopram | Citalopram may increase the hyponatremic activities of Metolazone. | Approved |
| Clenbuterol | Clenbuterol may increase the hypokalemic activities of Metolazone. | Approved, Vet Approved |
| Clevidipine | The risk or severity of adverse effects can be increased when Metolazone is combined with Clevidipine. | Approved |
| Clobetasol | Clobetasol may increase the hypokalemic activities of Metolazone. | Investigational |
| Clobetasol propionate | Clobetasol propionate may increase the hypokalemic activities of Metolazone. | Approved |
| Clocortolone | Clocortolone may increase the hypokalemic activities of Metolazone. | Approved |
| Clofarabine | The risk or severity of adverse effects can be increased when Metolazone is combined with Clofarabine. | Approved, Investigational |
| Clomipramine | The risk or severity of adverse effects can be increased when Metolazone is combined with Clomipramine. | Approved, Vet Approved |
| Clonidine | The risk or severity of adverse effects can be increased when Metolazone is combined with Clonidine. | Approved |
| Clonixin | The therapeutic efficacy of Metolazone can be decreased when used in combination with Clonixin. | Approved |
| Clozapine | The risk or severity of adverse effects can be increased when Metolazone is combined with Clozapine. | Approved |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Metolazone. | Approved, Illicit |
| Colesevelam | Colesevelam can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Colestipol | Colestipol can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Conivaptan | The risk or severity of adverse effects can be increased when Metolazone is combined with Conivaptan. | Approved, Investigational |
| Cortisone acetate | Cortisone acetate may increase the hypokalemic activities of Metolazone. | Approved |
| Cryptenamine | Metolazone may increase the hypotensive activities of Cryptenamine. | Approved |
| Curcumin | The therapeutic efficacy of Metolazone can be decreased when used in combination with Curcumin. | Investigational |
| Cyclopentolate | The serum concentration of Metolazone can be increased when it is combined with Cyclopentolate. | Approved |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Metolazone is combined with Cyclophosphamide. | Approved, Investigational |
| Cyclothiazide | Metolazone may increase the hypotensive activities of Cyclothiazide. | Approved |
| Dapagliflozin | The risk or severity of adverse effects can be increased when Metolazone is combined with Dapagliflozin. | Approved |
| Dapoxetine | Dapoxetine may increase the hyponatremic activities of Metolazone. | Investigational |
| Darifenacin | The serum concentration of Metolazone can be increased when it is combined with Darifenacin. | Approved, Investigational |
| Debrisoquin | Metolazone may increase the hypotensive activities of Debrisoquin. | Approved |
| Deoxyspergualin | The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Metolazone. | Investigational |
| Deserpidine | Metolazone may increase the hypotensive activities of Deserpidine. | Approved |
| Desflurane | The risk or severity of adverse effects can be increased when Metolazone is combined with Desflurane. | Approved |
| Deslanoside | The risk or severity of adverse effects can be increased when Metolazone is combined with Deslanoside. | Approved |
| Desloratadine | The serum concentration of Metolazone can be increased when it is combined with Desloratadine. | Approved, Investigational |
| Desoximetasone | Desoximetasone may increase the hypokalemic activities of Metolazone. | Approved |
| Desoxycorticosterone Pivalate | Desoxycorticosterone Pivalate may increase the hypokalemic activities of Metolazone. | Experimental, Vet Approved |
| Desvenlafaxine | Desvenlafaxine may increase the hyponatremic activities of Metolazone. | Approved |
| Dexamethasone | Dexamethasone may increase the hypokalemic activities of Metolazone. | Approved, Investigational, Vet Approved |
| Dexetimide | The serum concentration of Metolazone can be increased when it is combined with Dexetimide. | Withdrawn |
| Dexketoprofen | The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Metolazone. | Approved |
| Dexmedetomidine | The risk or severity of adverse effects can be increased when Metolazone is combined with Dexmedetomidine. | Approved, Vet Approved |
| Dextromoramide | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Metolazone. | Experimental, Illicit |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Metolazone. | Approved, Illicit, Withdrawn |
| Dezocine | The risk or severity of adverse effects can be increased when Dezocine is combined with Metolazone. | Approved |
| Diazoxide | The risk or severity of adverse effects can be increased when Metolazone is combined with Diazoxide. | Approved |
| Diclofenac | The therapeutic efficacy of Metolazone can be decreased when used in combination with Diclofenac. | Approved, Vet Approved |
| Diclofenamide | The risk or severity of adverse effects can be increased when Metolazone is combined with Diclofenamide. | Approved |
| Dicyclomine | The serum concentration of Metolazone can be increased when it is combined with Dicyclomine. | Approved |
| Diflorasone | Diflorasone may increase the hypokalemic activities of Metolazone. | Approved |
| Diflunisal | The therapeutic efficacy of Metolazone can be decreased when used in combination with Diflunisal. | Approved |
| Difluocortolone | Difluocortolone may increase the hypokalemic activities of Metolazone. | Approved |
| Difluprednate | Difluprednate may increase the hypokalemic activities of Metolazone. | Approved |
| Digitoxin | The risk or severity of adverse effects can be increased when Metolazone is combined with Digitoxin. | Approved |
| Digoxin | The risk or severity of adverse effects can be increased when Metolazone is combined with Digoxin. | Approved |
| Dihydralazine | Metolazone may increase the hypotensive activities of Dihydralazine. | Investigational |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metolazone. | Approved, Illicit |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Metolazone. | Experimental, Illicit |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Metolazone. | Experimental, Illicit |
| Dihydrotachysterol | Metolazone may increase the hypercalcemic activities of Dihydrotachysterol. | Approved |
| Diltiazem | The risk or severity of adverse effects can be increased when Diltiazem is combined with Metolazone. | Approved |
| Dinutuximab | The risk or severity of adverse effects can be increased when Metolazone is combined with Dinutuximab. | Approved |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Metolazone. | Approved, Illicit |
| Dipivefrin | Dipivefrin may increase the hypokalemic activities of Metolazone. | Approved |
| Dipyridamole | The risk or severity of adverse effects can be increased when Metolazone is combined with Dipyridamole. | Approved |
| Dobutamine | Dobutamine may increase the hypokalemic activities of Metolazone. | Approved |
| Dofetilide | Metolazone may increase the QTc-prolonging activities of Dofetilide. | Approved |
| Dorzolamide | Metolazone may increase the hypotensive activities of Dorzolamide. | Approved |
| Doxazosin | The risk or severity of adverse effects can be increased when Metolazone is combined with Doxazosin. | Approved |
| Doxercalciferol | Metolazone may increase the hypercalcemic activities of Doxercalciferol. | Approved |
| Droxicam | The therapeutic efficacy of Metolazone can be decreased when used in combination with Droxicam. | Approved |
| Droxidopa | Droxidopa may increase the hypokalemic activities of Metolazone. | Approved, Investigational |
| Dulaglutide | The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Metolazone. | Approved |
| Duloxetine | Metolazone may increase the orthostatic hypotensive activities of Duloxetine. | Approved |
| Duvelisib | The therapeutic efficacy of Metolazone can be decreased when used in combination with Duvelisib. | Investigational |
| E-6201 | The therapeutic efficacy of Metolazone can be decreased when used in combination with E6201. | Investigational |
| Ebselen | The therapeutic efficacy of Metolazone can be decreased when used in combination with Ebselen. | Investigational |
| Efonidipine | Metolazone may increase the hypotensive activities of Efonidipine. | Approved |
| Empagliflozin | The risk or severity of adverse effects can be increased when Metolazone is combined with Empagliflozin. | Approved |
| Enalapril | The risk or severity of adverse effects can be increased when Metolazone is combined with Enalapril. | Approved, Vet Approved |
| Enalaprilat | Metolazone may increase the hypotensive activities of Enalaprilat. | Approved |
| Ephedra | Ephedra may increase the hypokalemic activities of Metolazone. | Approved, Nutraceutical, Withdrawn |
| Epinephrine | Epinephrine may increase the hypokalemic activities of Metolazone. | Approved, Vet Approved |
| Epirizole | The therapeutic efficacy of Metolazone can be decreased when used in combination with Epirizole. | Approved |
| Eplerenone | The risk or severity of adverse effects can be increased when Metolazone is combined with Eplerenone. | Approved |
| Epoprostenol | Metolazone may increase the hypotensive activities of Epoprostenol. | Approved |
| Eprosartan | The risk or severity of adverse effects can be increased when Metolazone is combined with Eprosartan. | Approved |
| Equilenin | Equilenin may increase the hypokalemic activities of Metolazone. | Experimental |
| Equilin | Equilin may increase the hypokalemic activities of Metolazone. | Approved |
| Ergocalciferol | Metolazone may increase the hypercalcemic activities of Ergocalciferol. | Approved, Nutraceutical |
| Escitalopram | Escitalopram may increase the hyponatremic activities of Metolazone. | Approved, Investigational |
| Esmolol | The risk or severity of adverse effects can be increased when Esmolol is combined with Metolazone. | Approved |
| Estrone | Estrone may increase the hypokalemic activities of Metolazone. | Approved |
| Estrone sulfate | Estrone sulfate may increase the hypokalemic activities of Metolazone. | Approved |
| Etacrynic acid | The risk or severity of adverse effects can be increased when Metolazone is combined with Etacrynic acid. | Approved |
| Etanercept | The therapeutic efficacy of Metolazone can be decreased when used in combination with Etanercept. | Approved, Investigational |
| Ethanol | Ethanol may increase the orthostatic hypotensive activities of Metolazone. | Approved |
| Ethopropazine | The serum concentration of Metolazone can be increased when it is combined with Ethopropazine. | Approved |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Metolazone. | Approved, Illicit |
| Etodolac | The therapeutic efficacy of Metolazone can be decreased when used in combination with Etodolac. | Approved, Investigational, Vet Approved |
| Etofenamate | The therapeutic efficacy of Metolazone can be decreased when used in combination with Etofenamate. | Approved |
| Etoperidone | Etoperidone may increase the hyponatremic activities of Metolazone. | Approved |
| Etoricoxib | The therapeutic efficacy of Metolazone can be decreased when used in combination with Etoricoxib. | Approved, Investigational |
| Etorphine | The risk or severity of adverse effects can be increased when Etorphine is combined with Metolazone. | Illicit, Vet Approved |
| Exenatide | The therapeutic efficacy of Exenatide can be decreased when used in combination with Metolazone. | Approved, Investigational |
| Felodipine | The risk or severity of adverse effects can be increased when Metolazone is combined with Felodipine. | Approved, Investigational |
| Fenbufen | The therapeutic efficacy of Metolazone can be decreased when used in combination with Fenbufen. | Approved |
| Fenoldopam | Metolazone may increase the hypotensive activities of Fenoldopam. | Approved |
| Fenoprofen | The therapeutic efficacy of Metolazone can be decreased when used in combination with Fenoprofen. | Approved |
| Fenoterol | Fenoterol may increase the hypokalemic activities of Metolazone. | Approved |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Metolazone. | Approved, Illicit, Investigational, Vet Approved |
| Fesoterodine | The serum concentration of Metolazone can be increased when it is combined with Fesoterodine. | Approved |
| Fimasartan | The risk or severity of adverse effects can be increased when Metolazone is combined with Fimasartan. | Approved |
| Floctafenine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Floctafenine. | Approved, Withdrawn |
| Fludrocortisone | Fludrocortisone may increase the hypokalemic activities of Metolazone. | Approved |
| Flumethasone | Flumethasone may increase the hypokalemic activities of Metolazone. | Approved, Vet Approved |
| Flunisolide | Flunisolide may increase the hypokalemic activities of Metolazone. | Approved, Investigational |
| Fluocinolone Acetonide | Fluocinolone Acetonide may increase the hypokalemic activities of Metolazone. | Approved, Investigational, Vet Approved |
| Fluocinonide | Fluocinonide may increase the hypokalemic activities of Metolazone. | Approved, Investigational |
| Fluocortolone | Fluocortolone may increase the hypokalemic activities of Metolazone. | Approved, Withdrawn |
| Fluorometholone | Fluorometholone may increase the hypokalemic activities of Metolazone. | Approved |
| Fluoxetine | Fluoxetine may increase the hyponatremic activities of Metolazone. | Approved, Vet Approved |
| Fluprednidene | Fluprednidene may increase the hypokalemic activities of Metolazone. | Approved, Withdrawn |
| Flurandrenolide | Flurandrenolide may increase the hypokalemic activities of Metolazone. | Approved |
| Flurbiprofen | The therapeutic efficacy of Metolazone can be decreased when used in combination with Flurbiprofen. | Approved, Investigational |
| Fluticasone furoate | Fluticasone furoate may increase the hypokalemic activities of Metolazone. | Approved |
| Fluticasone propionate | Fluticasone Propionate may increase the hypokalemic activities of Metolazone. | Approved |
| Fluvoxamine | Fluvoxamine may increase the hyponatremic activities of Metolazone. | Approved, Investigational |
| Formestane | Formestane may increase the hypokalemic activities of Metolazone. | Approved, Investigational, Withdrawn |
| Formoterol | Formoterol may increase the hypokalemic activities of Metolazone. | Approved, Investigational |
| Fosinopril | The risk or severity of adverse effects can be increased when Fosinopril is combined with Metolazone. | Approved |
| Furazolidone | Furazolidone may increase the hypotensive activities of Metolazone. | Approved, Vet Approved |
| Furosemide | The risk or severity of adverse effects can be increased when Metolazone is combined with Furosemide. | Approved, Vet Approved |
| Gallamine Triethiodide | The serum concentration of Metolazone can be increased when it is combined with Gallamine Triethiodide. | Approved |
| Glibornuride | The therapeutic efficacy of Glibornuride can be decreased when used in combination with Metolazone. | Withdrawn |
| Gliclazide | The therapeutic efficacy of Gliclazide can be decreased when used in combination with Metolazone. | Approved |
| Glimepiride | The therapeutic efficacy of Glimepiride can be decreased when used in combination with Metolazone. | Approved |
| Glipizide | The therapeutic efficacy of Glipizide can be decreased when used in combination with Metolazone. | Approved |
| Gliquidone | The therapeutic efficacy of Gliquidone can be decreased when used in combination with Metolazone. | Approved |
| Glyburide | The therapeutic efficacy of Glyburide can be decreased when used in combination with Metolazone. | Approved |
| Glycopyrronium | The serum concentration of Metolazone can be increased when it is combined with Glycopyrronium. | Approved, Investigational, Vet Approved |
| Guanabenz | Metolazone may increase the hypotensive activities of Guanabenz. | Approved |
| Guanadrel | Guanadrel may increase the hypotensive activities of Metolazone. | Approved |
| Guanethidine | Metolazone may increase the hypotensive activities of Guanethidine. | Approved |
| Guanfacine | The risk or severity of adverse effects can be increased when Metolazone is combined with Guanfacine. | Approved, Investigational |
| Gusperimus | The therapeutic efficacy of Gusperimus can be decreased when used in combination with Metolazone. | Investigational |
| Halothane | The risk or severity of adverse effects can be increased when Metolazone is combined with Halothane. | Approved, Vet Approved |
| HE3286 | HE3286 may increase the hypokalemic activities of Metolazone. | Investigational |
| Heroin | The risk or severity of adverse effects can be increased when Heroin is combined with Metolazone. | Approved, Illicit |
| Hexamethonium | The serum concentration of Metolazone can be increased when it is combined with Hexamethonium. | Experimental |
| Hexobarbital | Hexobarbital may increase the orthostatic hypotensive activities of Metolazone. | Approved |
| Higenamine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Higenamine. | Investigational |
| Hydracarbazine | Hydracarbazine may increase the hypotensive activities of Metolazone. | Experimental |
| Hydralazine | The risk or severity of adverse effects can be increased when Metolazone is combined with Hydralazine. | Approved |
| Hydrochlorothiazide | The risk or severity of adverse effects can be increased when Metolazone is combined with Hydrochlorothiazide. | Approved, Vet Approved |
| Hydrocodone | The risk or severity of adverse effects can be increased when Hydrocodone is combined with Metolazone. | Approved, Illicit |
| Hydrocortisone | Hydrocortisone may increase the hypokalemic activities of Metolazone. | Approved, Vet Approved |
| Hydroflumethiazide | Metolazone may increase the hypotensive activities of Hydroflumethiazide. | Approved |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Metolazone. | Approved, Illicit |
| Hyoscyamine | The serum concentration of Metolazone can be increased when it is combined with Hyoscyamine. | Approved |
| Ibuprofen | The therapeutic efficacy of Metolazone can be decreased when used in combination with Ibuprofen. | Approved |
| Ibuproxam | The therapeutic efficacy of Metolazone can be decreased when used in combination with Ibuproxam. | Withdrawn |
| Icatibant | The therapeutic efficacy of Metolazone can be decreased when used in combination with Icatibant. | Approved |
| Iloprost | Iloprost may increase the hypotensive activities of Metolazone. | Approved, Investigational |
| Imidapril | The risk or severity of adverse effects can be increased when Metolazone is combined with Imidapril. | Investigational |
| Imipramine | The risk or severity of adverse effects can be increased when Metolazone is combined with Imipramine. | Approved |
| Indacaterol | Indacaterol may increase the hypokalemic activities of Metolazone. | Approved |
| Indalpine | Indalpine may increase the hyponatremic activities of Metolazone. | Investigational, Withdrawn |
| Indapamide | The risk or severity of adverse effects can be increased when Metolazone is combined with Indapamide. | Approved |
| Indenolol | Metolazone may increase the hypotensive activities of Indenolol. | Withdrawn |
| Indomethacin | The therapeutic efficacy of Metolazone can be decreased when used in combination with Indomethacin. | Approved, Investigational |
| Indoprofen | The therapeutic efficacy of Metolazone can be decreased when used in combination with Indoprofen. | Withdrawn |
| Indoramin | Metolazone may increase the hypotensive activities of Indoramin. | Withdrawn |
| Insulin Aspart | The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Metolazone. | Approved |
| Insulin Detemir | The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Metolazone. | Approved |
| Insulin Glargine | The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Metolazone. | Approved |
| Insulin Glulisine | The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Metolazone. | Approved |
| Insulin Lispro | The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Metolazone. | Approved |
| Insulin Pork | The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Metolazone. | Approved |
| Ipratropium bromide | The serum concentration of Metolazone can be increased when it is combined with Ipratropium bromide. | Approved |
| Iproclozide | Iproclozide may increase the hypotensive activities of Metolazone. | Withdrawn |
| Iproniazid | Iproniazid may increase the hypotensive activities of Metolazone. | Withdrawn |
| Irbesartan | The risk or severity of adverse effects can be increased when Metolazone is combined with Irbesartan. | Approved, Investigational |
| Isocarboxazid | Isocarboxazid may increase the hypotensive activities of Metolazone. | Approved |
| Isoetarine | Isoetarine may increase the hypokalemic activities of Metolazone. | Approved |
| Isoflurane | The risk or severity of adverse effects can be increased when Metolazone is combined with Isoflurane. | Approved, Vet Approved |
| Isoprenaline | Isoprenaline may increase the hypokalemic activities of Metolazone. | Approved |
| Isosorbide Dinitrate | The risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Dinitrate. | Approved |
| Isosorbide Mononitrate | The risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Mononitrate. | Approved |
| Isoxicam | The therapeutic efficacy of Metolazone can be decreased when used in combination with Isoxicam. | Withdrawn |
| Isoxsuprine | The risk or severity of adverse effects can be increased when Metolazone is combined with Isoxsuprine. | Approved, Withdrawn |
| Isradipine | The risk or severity of adverse effects can be increased when Isradipine is combined with Metolazone. | Approved |
| Ivabradine | Metolazone may increase the arrhythmogenic activities of Ivabradine. | Approved |
| Kebuzone | The therapeutic efficacy of Metolazone can be decreased when used in combination with Kebuzone. | Experimental |
| Ketanserin | Metolazone may increase the hypotensive activities of Ketanserin. | Investigational |
| Ketobemidone | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Metolazone. | Approved |
| Ketoprofen | The therapeutic efficacy of Metolazone can be decreased when used in combination with Ketoprofen. | Approved, Vet Approved |
| Ketorolac | The therapeutic efficacy of Metolazone can be decreased when used in combination with Ketorolac. | Approved |
| Labetalol | The risk or severity of adverse effects can be increased when Metolazone is combined with Labetalol. | Approved |
| Lacidipine | Metolazone may increase the hypotensive activities of Lacidipine. | Approved |
| Latanoprost | Metolazone may increase the hypotensive activities of Latanoprost. | Approved, Investigational |
| Leflunomide | The therapeutic efficacy of Metolazone can be decreased when used in combination with Leflunomide. | Approved, Investigational |
| Lercanidipine | Metolazone may increase the hypotensive activities of Lercanidipine. | Approved, Investigational |
| Levobunolol | The risk or severity of adverse effects can be increased when Metolazone is combined with Levobunolol. | Approved |
| Levobupivacaine | The risk or severity of adverse effects can be increased when Metolazone is combined with Levobupivacaine. | Approved |
| Levodopa | Metolazone may increase the orthostatic hypotensive activities of Levodopa. | Approved |
| Levomethadyl Acetate | The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Metolazone. | Approved |
| Levomilnacipran | Levomilnacipran may increase the hyponatremic activities of Metolazone. | Approved |
| Levorphanol | The risk or severity of adverse effects can be increased when Levorphanol is combined with Metolazone. | Approved |
| Levosimendan | The risk or severity of adverse effects can be increased when Metolazone is combined with Levosimendan. | Approved, Investigational |
| Linagliptin | The therapeutic efficacy of Linagliptin can be decreased when used in combination with Metolazone. | Approved |
| Liraglutide | The therapeutic efficacy of Liraglutide can be decreased when used in combination with Metolazone. | Approved |
| Lisinopril | The risk or severity of adverse effects can be increased when Metolazone is combined with Lisinopril. | Approved, Investigational |
| Lisofylline | The therapeutic efficacy of Metolazone can be decreased when used in combination with Lisofylline. | Investigational |
| Lithium | Metolazone may decrease the excretion rate of Lithium which could result in a higher serum level. | Approved |
| Lofentanil | The risk or severity of adverse effects can be increased when Lofentanil is combined with Metolazone. | Illicit |
| Lofexidine | Metolazone may increase the hypotensive activities of Lofexidine. | Approved, Investigational |
| Lornoxicam | The therapeutic efficacy of Metolazone can be decreased when used in combination with Lornoxicam. | Approved |
| Losartan | The risk or severity of adverse effects can be increased when Metolazone is combined with Losartan. | Approved |
| Loxoprofen | The therapeutic efficacy of Metolazone can be decreased when used in combination with Loxoprofen. | Approved |
| Lumiracoxib | The therapeutic efficacy of Metolazone can be decreased when used in combination with Lumiracoxib. | Approved, Investigational |
| Macitentan | Metolazone may increase the hypotensive activities of Macitentan. | Approved |
| Magnesium salicylate | The therapeutic efficacy of Metolazone can be decreased when used in combination with Magnesium salicylate. | Approved |
| Manidipine | Metolazone may increase the hypotensive activities of Manidipine. | Approved |
| Mannitol | The risk or severity of adverse effects can be increased when Metolazone is combined with Mannitol. | Approved, Investigational |
| Masoprocol | The therapeutic efficacy of Metolazone can be decreased when used in combination with Masoprocol. | Approved |
| ME-609 | ME-609 may increase the hypokalemic activities of Metolazone. | Investigational |
| Mebanazine | Mebanazine may increase the hypotensive activities of Metolazone. | Withdrawn |
| Mecamylamine | The risk or severity of adverse effects can be increased when Metolazone is combined with Mecamylamine. | Approved |
| Meclofenamic acid | The therapeutic efficacy of Metolazone can be decreased when used in combination with Meclofenamic acid. | Approved, Vet Approved |
| Medrysone | Medrysone may increase the hypokalemic activities of Metolazone. | Approved |
| Mefenamic acid | The therapeutic efficacy of Metolazone can be decreased when used in combination with Mefenamic acid. | Approved |
| Meloxicam | The therapeutic efficacy of Metolazone can be decreased when used in combination with Meloxicam. | Approved, Vet Approved |
| Mesalazine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Mesalazine. | Approved |
| Metamizole | The therapeutic efficacy of Metolazone can be decreased when used in combination with Metamizole. | Withdrawn |
| Metformin | The therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone. | Approved |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Metolazone. | Approved |
| Methadyl Acetate | The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Metolazone. | Approved, Illicit |
| Methantheline | The serum concentration of Metolazone can be increased when it is combined with Methantheline. | Approved |
| Methazolamide | The risk or severity of adverse effects can be increased when Metolazone is combined with Methazolamide. | Approved |
| Methohexital | Methohexital may increase the orthostatic hypotensive activities of Metolazone. | Approved |
| Methyclothiazide | The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metolazone. | Approved |
| Methyldopa | The risk or severity of adverse effects can be increased when Metolazone is combined with Methyldopa. | Approved |
| Methylene blue | Methylene blue may increase the hypotensive activities of Metolazone. | Investigational |
| Methylphenidate | Methylphenidate may decrease the antihypertensive activities of Metolazone. | Approved, Investigational |
| Methylphenobarbital | Methylphenobarbital may increase the orthostatic hypotensive activities of Metolazone. | Approved |
| Methylprednisolone | Methylprednisolone may increase the hypokalemic activities of Metolazone. | Approved, Vet Approved |
| Metipranolol | The risk or severity of adverse effects can be increased when Metolazone is combined with Metipranolol. | Approved |
| Metixene | The serum concentration of Metolazone can be increased when it is combined with Metixene. | Approved |
| Metoprolol | The risk or severity of adverse effects can be increased when Metoprolol is combined with Metolazone. | Approved, Investigational |
| Metyrosine | Metolazone may increase the hypotensive activities of Metyrosine. | Approved |
| Mibefradil | Metolazone may increase the hypotensive activities of Mibefradil. | Withdrawn |
| Miglitol | The therapeutic efficacy of Miglitol can be decreased when used in combination with Metolazone. | Approved |
| Miglustat | The therapeutic efficacy of Miglustat can be decreased when used in combination with Metolazone. | Approved |
| Milnacipran | Milnacipran may increase the hyponatremic activities of Metolazone. | Approved |
| Minaprine | Minaprine may increase the hypotensive activities of Metolazone. | Approved |
| Minoxidil | The risk or severity of adverse effects can be increased when Minoxidil is combined with Metolazone. | Approved |
| Mitiglinide | The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Metolazone. | Approved, Investigational |
| Mizoribine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Mizoribine. | Investigational |
| Moclobemide | Moclobemide may increase the hypotensive activities of Metolazone. | Approved |
| Moexipril | The risk or severity of adverse effects can be increased when Metolazone is combined with Moexipril. | Approved |
| Molsidomine | Molsidomine may increase the hypotensive activities of Metolazone. | Approved |
| Mometasone | Mometasone may increase the hypokalemic activities of Metolazone. | Approved, Vet Approved |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Metolazone. | Approved, Investigational |
| Moxonidine | Metolazone may increase the hypotensive activities of Moxonidine. | Approved |
| Mycophenolate mofetil | The therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolate mofetil. | Approved, Investigational |
| Mycophenolic acid | The therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolic acid. | Approved |
| Nabilone | The risk or severity of adverse effects can be increased when Metolazone is combined with Nabilone. | Approved, Investigational |
| Nabumetone | The therapeutic efficacy of Metolazone can be decreased when used in combination with Nabumetone. | Approved |
| Nadolol | The risk or severity of adverse effects can be increased when Metolazone is combined with Nadolol. | Approved |
| Nafamostat | The therapeutic efficacy of Metolazone can be decreased when used in combination with Nafamostat. | Approved, Investigational |
| Naftifine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Naftifine. | Approved |
| Naftopidil | Metolazone may increase the hypotensive activities of Naftopidil. | Investigational |
| Nalbuphine | The risk or severity of adverse effects can be increased when Nalbuphine is combined with Metolazone. | Approved |
| Naproxen | The therapeutic efficacy of Metolazone can be decreased when used in combination with Naproxen. | Approved, Vet Approved |
| Nateglinide | The therapeutic efficacy of Nateglinide can be decreased when used in combination with Metolazone. | Approved, Investigational |
| NCX 1022 | NCX 1022 may increase the hypokalemic activities of Metolazone. | Investigational |
| NCX 4016 | The therapeutic efficacy of Metolazone can be decreased when used in combination with NCX 4016. | Investigational |
| Nebivolol | The risk or severity of adverse effects can be increased when Metolazone is combined with Nebivolol. | Approved, Investigational |
| Nefazodone | Nefazodone may increase the hyponatremic activities of Metolazone. | Approved, Withdrawn |
| Nepafenac | The therapeutic efficacy of Metolazone can be decreased when used in combination with Nepafenac. | Approved |
| Nesiritide | The risk or severity of adverse effects can be increased when Metolazone is combined with Nesiritide. | Approved, Investigational |
| Nialamide | Nialamide may increase the hypotensive activities of Metolazone. | Withdrawn |
| Nicardipine | The risk or severity of adverse effects can be increased when Metolazone is combined with Nicardipine. | Approved |
| Nicorandil | Nicorandil may increase the hypotensive activities of Metolazone. | Approved |
| Nifedipine | The risk or severity of adverse effects can be increased when Metolazone is combined with Nifedipine. | Approved |
| Niflumic Acid | The therapeutic efficacy of Metolazone can be decreased when used in combination with Niflumic Acid. | Approved |
| Niguldipine | Metolazone may increase the hypotensive activities of Niguldipine. | Experimental |
| Nilvadipine | Metolazone may increase the hypotensive activities of Nilvadipine. | Approved |
| Nimesulide | The therapeutic efficacy of Metolazone can be decreased when used in combination with Nimesulide. | Approved, Withdrawn |
| Nimodipine | The risk or severity of adverse effects can be increased when Nimodipine is combined with Metolazone. | Approved |
| Nisoldipine | The risk or severity of adverse effects can be increased when Nisoldipine is combined with Metolazone. | Approved |
| Nitrendipine | Metolazone may increase the hypotensive activities of Nitrendipine. | Approved |
| Nitric Oxide | The risk or severity of adverse effects can be increased when Metolazone is combined with Nitric Oxide. | Approved |
| Nitroaspirin | The therapeutic efficacy of Metolazone can be decreased when used in combination with Nitroaspirin. | Investigational |
| Nitroglycerin | The risk or severity of adverse effects can be increased when Metolazone is combined with Nitroglycerin. | Approved, Investigational |
| Nitroprusside | The risk or severity of adverse effects can be increased when Nitroprusside is combined with Metolazone. | Approved |
| Norepinephrine | Norepinephrine may increase the hypokalemic activities of Metolazone. | Approved |
| Normethadone | The risk or severity of adverse effects can be increased when Normethadone is combined with Metolazone. | Approved, Illicit |
| Obinutuzumab | Metolazone may increase the hypotensive activities of Obinutuzumab. | Approved |
| Octamoxin | Octamoxin may increase the hypotensive activities of Metolazone. | Withdrawn |
| Oleandrin | The risk or severity of adverse effects can be increased when Metolazone is combined with Anvirzel. | Experimental |
| Oleoyl-estrone | Oleoyl estrone may increase the hypokalemic activities of Metolazone. | Investigational |
| Olmesartan | The risk or severity of adverse effects can be increased when Olmesartan is combined with Metolazone. | Approved, Investigational |
| Olodaterol | Olodaterol may increase the hypokalemic activities of Metolazone. | Approved |
| Olopatadine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Olopatadine. | Approved |
| Olsalazine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Olsalazine. | Approved |
| Omapatrilat | Metolazone may increase the hypotensive activities of Omapatrilat. | Investigational |
| Opium | The risk or severity of adverse effects can be increased when Opium is combined with Metolazone. | Approved, Illicit |
| Orciprenaline | Orciprenaline may increase the hypokalemic activities of Metolazone. | Approved |
| Orphenadrine | The serum concentration of Metolazone can be increased when it is combined with Orphenadrine. | Approved |
| Ouabain | The risk or severity of adverse effects can be increased when Metolazone is combined with Ouabain. | Approved |
| Oxaprozin | The therapeutic efficacy of Metolazone can be decreased when used in combination with Oxaprozin. | Approved |
| Oxcarbazepine | The risk or severity of adverse effects can be increased when Metolazone is combined with Oxcarbazepine. | Approved |
| Oxprenolol | Metolazone may increase the hypotensive activities of Oxprenolol. | Approved |
| Oxybutynin | The serum concentration of Metolazone can be increased when it is combined with Oxybutynin. | Approved, Investigational |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with Metolazone. | Approved, Illicit, Investigational |
| Oxymorphone | The risk or severity of adverse effects can be increased when Oxymorphone is combined with Metolazone. | Approved, Investigational, Vet Approved |
| Oxyphenbutazone | The therapeutic efficacy of Metolazone can be decreased when used in combination with Oxyphenbutazone. | Withdrawn |
| Oxyphenonium | The serum concentration of Metolazone can be increased when it is combined with Oxyphenonium. | Approved |
| Paclitaxel | The risk or severity of adverse effects can be increased when Metolazone is combined with Paclitaxel. | Approved, Vet Approved |
| Pancuronium | The serum concentration of Metolazone can be increased when it is combined with Pancuronium. | Approved |
| Papaverine | The risk or severity of adverse effects can be increased when Metolazone is combined with Papaverine. | Approved |
| Paramethasone | Paramethasone may increase the hypokalemic activities of Metolazone. | Approved |
| Parecoxib | The therapeutic efficacy of Metolazone can be decreased when used in combination with Parecoxib. | Approved |
| Pargyline | Pargyline may increase the hypotensive activities of Metolazone. | Approved |
| Paricalcitol | Metolazone may increase the hypercalcemic activities of Paricalcitol. | Approved, Investigational |
| Paroxetine | Paroxetine may increase the hyponatremic activities of Metolazone. | Approved, Investigational |
| Penbutolol | The risk or severity of adverse effects can be increased when Metolazone is combined with Penbutolol. | Approved, Investigational |
| Pentazocine | The risk or severity of adverse effects can be increased when Pentazocine is combined with Metolazone. | Approved, Vet Approved |
| Pentobarbital | Pentobarbital may increase the orthostatic hypotensive activities of Metolazone. | Approved, Vet Approved |
| Pentolinium | The serum concentration of Metolazone can be increased when it is combined with Pentolinium. | Approved |
| Pentoxifylline | Pentoxifylline may increase the hypotensive activities of Metolazone. | Approved, Investigational |
| Perindopril | The risk or severity of adverse effects can be increased when Metolazone is combined with Perindopril. | Approved |
| Pethidine | The risk or severity of adverse effects can be increased when Pethidine is combined with Metolazone. | Approved |
| Phenelzine | Phenelzine may increase the hypotensive activities of Metolazone. | Approved |
| Phenformin | The therapeutic efficacy of Phenformin can be decreased when used in combination with Metolazone. | Approved, Withdrawn |
| Pheniprazine | Pheniprazine may increase the hypotensive activities of Metolazone. | Withdrawn |
| Phenobarbital | Phenobarbital may increase the orthostatic hypotensive activities of Metolazone. | Approved |
| Phenoxybenzamine | Metolazone may increase the hypotensive activities of Phenoxybenzamine. | Approved |
| Phenoxypropazine | Phenoxypropazine may increase the hypotensive activities of Metolazone. | Withdrawn |
| Phentolamine | Metolazone may increase the hypotensive activities of Phentolamine. | Approved |
| Phenylbutazone | The therapeutic efficacy of Metolazone can be decreased when used in combination with Phenylbutazone. | Approved, Vet Approved |
| Phenylpropanolamine | Phenylpropanolamine may increase the hypokalemic activities of Metolazone. | Approved, Vet Approved, Withdrawn |
| Pimecrolimus | The therapeutic efficacy of Metolazone can be decreased when used in combination with Pimecrolimus. | Approved, Investigational |
| Pindolol | The risk or severity of adverse effects can be increased when Metolazone is combined with Pindolol. | Approved |
| Pioglitazone | The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Metolazone. | Approved, Investigational |
| Pipamperone | The risk or severity of adverse effects can be increased when Metolazone is combined with Pipamperone. | Approved |
| Pipecuronium | The serum concentration of Metolazone can be increased when it is combined with Pipecuronium. | Approved |
| Pirbuterol | Pirbuterol may increase the hypokalemic activities of Metolazone. | Approved |
| Pirenzepine | The serum concentration of Metolazone can be increased when it is combined with Pirenzepine. | Approved |
| Pirfenidone | The therapeutic efficacy of Metolazone can be decreased when used in combination with Pirfenidone. | Investigational |
| Piritramide | The risk or severity of adverse effects can be increased when Piritramide is combined with Metolazone. | Investigational |
| Pirlindole | Pirlindole may increase the hypotensive activities of Metolazone. | Approved |
| Piroxicam | The therapeutic efficacy of Metolazone can be decreased when used in combination with Piroxicam. | Approved, Investigational |
| Pivhydrazine | Pivhydrazine may increase the hypotensive activities of Metolazone. | Withdrawn |
| Polythiazide | Metolazone may increase the hypotensive activities of Polythiazide. | Approved |
| Pramipexole | The risk or severity of adverse effects can be increased when Metolazone is combined with Pramipexole. | Approved, Investigational |
| Pramlintide | The therapeutic efficacy of Pramlintide can be decreased when used in combination with Metolazone. | Approved, Investigational |
| Prasterone | Prasterone may increase the hypokalemic activities of Metolazone. | Approved, Nutraceutical |
| Prasterone sulfate | dehydroepiandrosterone sulfate may increase the hypokalemic activities of Metolazone. | Investigational |
| Prazosin | The risk or severity of adverse effects can be increased when Prazosin is combined with Metolazone. | Approved |
| Prednicarbate | Prednicarbate may increase the hypokalemic activities of Metolazone. | Approved |
| Prednisolone | Prednisolone may increase the hypokalemic activities of Metolazone. | Approved, Vet Approved |
| Prednisone | Prednisone may increase the hypokalemic activities of Metolazone. | Approved, Vet Approved |
| Pregnenolone | Pregnenolone may increase the hypokalemic activities of Metolazone. | Experimental |
| Primidone | Primidone may increase the orthostatic hypotensive activities of Metolazone. | Approved, Vet Approved |
| Procaterol | Procaterol may increase the hypokalemic activities of Metolazone. | Approved |
| Procyclidine | The serum concentration of Metolazone can be increased when it is combined with Procyclidine. | Approved |
| Propacetamol | The therapeutic efficacy of Metolazone can be decreased when used in combination with Propacetamol. | Approved |
| Propantheline | The serum concentration of Metolazone can be increased when it is combined with Propantheline. | Approved |
| Propiverine | The serum concentration of Metolazone can be increased when it is combined with Propiverine. | Investigational |
| Propofol | The risk or severity of adverse effects can be increased when Metolazone is combined with Propofol. | Approved, Investigational, Vet Approved |
| Propranolol | The risk or severity of adverse effects can be increased when Metolazone is combined with Propranolol. | Approved, Investigational |
| PTC299 | The therapeutic efficacy of Metolazone can be decreased when used in combination with PTC299. | Investigational |
| Quetiapine | The risk or severity of adverse effects can be increased when Metolazone is combined with Quetiapine. | Approved |
| Quinapril | The risk or severity of adverse effects can be increased when Metolazone is combined with Quinapril. | Approved, Investigational |
| Quinidine | The serum concentration of Metolazone can be increased when it is combined with Quinidine. | Approved |
| Quinine | Quinine may increase the hypotensive activities of Metolazone. | Approved |
| Ramipril | The risk or severity of adverse effects can be increased when Ramipril is combined with Metolazone. | Approved |
| Rasagiline | Rasagiline may increase the hypotensive activities of Metolazone. | Approved |
| Remifentanil | The risk or severity of adverse effects can be increased when Remifentanil is combined with Metolazone. | Approved |
| Remikiren | Remikiren may increase the hypotensive activities of Metolazone. | Approved |
| Repaglinide | The therapeutic efficacy of Repaglinide can be decreased when used in combination with Metolazone. | Approved, Investigational |
| Rescinnamine | Metolazone may increase the hypotensive activities of Rescinnamine. | Approved |
| Reserpine | The risk or severity of adverse effects can be increased when Reserpine is combined with Metolazone. | Approved |
| Resveratrol | The therapeutic efficacy of Metolazone can be decreased when used in combination with Resveratrol. | Experimental, Investigational |
| Rilmenidine | Metolazone may increase the hypotensive activities of Rilmenidine. | Investigational |
| Rimexolone | Rimexolone may increase the hypokalemic activities of Metolazone. | Approved |
| Riociguat | The risk or severity of adverse effects can be increased when Metolazone is combined with Riociguat. | Approved |
| Risperidone | Metolazone may increase the hypotensive activities of Risperidone. | Approved, Investigational |
| Ritodrine | Ritodrine may increase the hypokalemic activities of Metolazone. | Approved |
| Rituximab | Metolazone may increase the hypotensive activities of Rituximab. | Approved |
| Rofecoxib | The therapeutic efficacy of Metolazone can be decreased when used in combination with Rofecoxib. | Investigational, Withdrawn |
| Ropinirole | The risk or severity of adverse effects can be increased when Metolazone is combined with Ropinirole. | Approved, Investigational |
| Ropivacaine | The risk or severity of adverse effects can be increased when Metolazone is combined with Ropivacaine. | Approved |
| Rosiglitazone | The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Metolazone. | Approved, Investigational |
| Rotigotine | The risk or severity of adverse effects can be increased when Metolazone is combined with Rotigotine. | Approved |
| Sacubitril | The risk or severity of adverse effects can be increased when Metolazone is combined with Sacubitril. | Approved |
| Safrazine | Safrazine may increase the hypotensive activities of Metolazone. | Withdrawn |
| Salbutamol | Salbutamol may increase the hypokalemic activities of Metolazone. | Approved, Vet Approved |
| Salicylamide | The therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylamide. | Approved |
| Salicylic acid | The therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylic acid. | Approved, Vet Approved |
| Salmeterol | Salmeterol may increase the hypokalemic activities of Metolazone. | Approved |
| Salsalate | The therapeutic efficacy of Metolazone can be decreased when used in combination with Salsalate. | Approved |
| Saprisartan | Metolazone may increase the hypotensive activities of Saprisartan. | Experimental |
| Saxagliptin | The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Metolazone. | Approved |
| Scopolamine | The serum concentration of Metolazone can be increased when it is combined with Scopolamine. | Approved |
| Scopolamine butylbromide | The serum concentration of Metolazone can be increased when it is combined with Scopolamine butylbromide. | Approved, Vet Approved |
| Secobarbital | Secobarbital may increase the orthostatic hypotensive activities of Metolazone. | Approved, Vet Approved |
| Selegiline | Selegiline may increase the hypotensive activities of Metolazone. | Approved, Investigational, Vet Approved |
| Selexipag | Metolazone may increase the hypotensive activities of Selexipag. | Approved |
| Sertraline | Sertraline may increase the hyponatremic activities of Metolazone. | Approved |
| Sevoflurane | The risk or severity of adverse effects can be increased when Metolazone is combined with Sevoflurane. | Approved, Vet Approved |
| Sildenafil | Sildenafil may increase the antihypertensive activities of Metolazone. | Approved, Investigational |
| Sitagliptin | The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Metolazone. | Approved, Investigational |
| Sitaxentan | Metolazone may increase the hypotensive activities of Sitaxentan. | Approved, Investigational, Withdrawn |
| Sodium Nitrite | The risk or severity of adverse effects can be increased when Metolazone is combined with Sodium Nitrite. | Approved |
| Solifenacin | The serum concentration of Metolazone can be increased when it is combined with Solifenacin. | Approved |
| Sotalol | The risk or severity of adverse effects can be increased when Sotalol is combined with Metolazone. | Approved |
| Spirapril | Metolazone may increase the hypotensive activities of Spirapril. | Approved |
| Spironolactone | The risk or severity of adverse effects can be increased when Spironolactone is combined with Metolazone. | Approved |
| SRT501 | The therapeutic efficacy of Metolazone can be decreased when used in combination with SRT501. | Investigational |
| Streptokinase | The risk or severity of adverse effects can be increased when Metolazone is combined with Streptokinase. | Approved |
| Sufentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Metolazone. | Approved, Investigational |
| Sulfasalazine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Sulfasalazine. | Approved |
| Sulindac | The therapeutic efficacy of Metolazone can be decreased when used in combination with Sulindac. | Approved |
| Sulodexide | The therapeutic efficacy of Sulodexide can be decreased when used in combination with Metolazone. | Approved, Investigational |
| Sulpiride | The risk or severity of adverse effects can be increased when Metolazone is combined with Sulpiride. | Approved |
| Suprofen | The therapeutic efficacy of Metolazone can be decreased when used in combination with Suprofen. | Approved, Withdrawn |
| Tadalafil | Tadalafil may increase the antihypertensive activities of Metolazone. | Approved, Investigational |
| Tamsulosin | The risk or severity of adverse effects can be increased when Metolazone is combined with Tamsulosin. | Approved, Investigational |
| Tapentadol | The risk or severity of adverse effects can be increased when Tapentadol is combined with Metolazone. | Approved |
| Telmisartan | The risk or severity of adverse effects can be increased when Metolazone is combined with Telmisartan. | Approved, Investigational |
| Temocapril | Metolazone may increase the hypotensive activities of Temocapril. | Experimental, Investigational |
| Tenoxicam | The therapeutic efficacy of Metolazone can be decreased when used in combination with Tenoxicam. | Approved |
| Terazosin | The risk or severity of adverse effects can be increased when Metolazone is combined with Terazosin. | Approved |
| Terbutaline | Terbutaline may increase the hypokalemic activities of Metolazone. | Approved |
| Teriflunomide | The therapeutic efficacy of Metolazone can be decreased when used in combination with Teriflunomide. | Approved |
| Terlipressin | Metolazone may increase the hypotensive activities of Terlipressin. | Approved, Investigational |
| Thalidomide | The risk or severity of adverse effects can be increased when Metolazone is combined with Thalidomide. | Approved, Investigational, Withdrawn |
| Thiamylal | Thiamylal may increase the orthostatic hypotensive activities of Metolazone. | Approved, Vet Approved |
| Thiopental | Thiopental may increase the orthostatic hypotensive activities of Metolazone. | Approved, Vet Approved |
| Thioridazine | The risk or severity of adverse effects can be increased when Metolazone is combined with Thioridazine. | Withdrawn |
| Tiaprofenic acid | The therapeutic efficacy of Metolazone can be decreased when used in combination with Tiaprofenic acid. | Approved |
| Tibolone | Metolazone may increase the hypotensive activities of Tibolone. | Approved |
| Ticrynafen | Metolazone may increase the hypotensive activities of Ticrynafen. | Withdrawn |
| Timolol | The risk or severity of adverse effects can be increased when Timolol is combined with Metolazone. | Approved |
| Tinoridine | The therapeutic efficacy of Metolazone can be decreased when used in combination with Tinoridine. | Investigational |
| Tiotropium | The serum concentration of Metolazone can be increased when it is combined with Tiotropium. | Approved |
| Tixocortol | Tixocortol may increase the hypokalemic activities of Metolazone. | Approved |
| Tizanidine | The risk or severity of adverse effects can be increased when Metolazone is combined with Tizanidine. | Approved |
| Tolazamide | The therapeutic efficacy of Tolazamide can be decreased when used in combination with Metolazone. | Approved |
| Tolazoline | Metolazone may increase the hypotensive activities of Tolazoline. | Approved, Vet Approved |
| Tolbutamide | The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Metolazone. | Approved |
| Tolcapone | The risk or severity of adverse effects can be increased when Metolazone is combined with Tolcapone. | Approved, Withdrawn |
| Tolfenamic Acid | The therapeutic efficacy of Metolazone can be decreased when used in combination with Tolfenamic Acid. | Approved |
| Tolmetin | The therapeutic efficacy of Metolazone can be decreased when used in combination with Tolmetin. | Approved |
| Toloxatone | Toloxatone may increase the hypotensive activities of Metolazone. | Approved |
| Tolterodine | The serum concentration of Metolazone can be increased when it is combined with Tolterodine. | Approved, Investigational |
| Topiramate | Metolazone may increase the hypokalemic activities of Topiramate. | Approved |
| Torasemide | The risk or severity of adverse effects can be increased when Torasemide is combined with Metolazone. | Approved |
| Toremifene | Metolazone may increase the hypercalcemic activities of Toremifene. | Approved, Investigational |
| Tramadol | The risk or severity of adverse effects can be increased when Tramadol is combined with Metolazone. | Approved, Investigational |
| Trandolapril | The risk or severity of adverse effects can be increased when Trandolapril is combined with Metolazone. | Approved |
| Tranilast | The therapeutic efficacy of Metolazone can be decreased when used in combination with Tranilast. | Approved, Investigational |
| Trans-2-Phenylcyclopropylamine | Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Metolazone. | Experimental |
| Tranylcypromine | Tranylcypromine may increase the hypotensive activities of Metolazone. | Approved |
| Travoprost | Travoprost may increase the hypotensive activities of Metolazone. | Approved |
| Treprostinil | Treprostinil may increase the hypotensive activities of Metolazone. | Approved, Investigational |
| Tretinoin | The risk or severity of adverse effects can be increased when Metolazone is combined with Tretinoin. | Approved, Investigational, Nutraceutical |
| Triamcinolone | Triamcinolone may increase the hypokalemic activities of Metolazone. | Approved, Vet Approved |
| Triamterene | The risk or severity of adverse effects can be increased when Triamterene is combined with Metolazone. | Approved |
| Trichlormethiazide | Metolazone may increase the hypotensive activities of Trichlormethiazide. | Approved, Vet Approved |
| Trihexyphenidyl | The serum concentration of Metolazone can be increased when it is combined with Trihexyphenidyl. | Approved |
| Trimazosin | Metolazone may increase the hypotensive activities of Trimazosin. | Experimental |
| Trimethaphan | The serum concentration of Metolazone can be increased when it is combined with Trimethaphan. | Approved |
| Troglitazone | The therapeutic efficacy of Troglitazone can be decreased when used in combination with Metolazone. | Withdrawn |
| Tropicamide | The serum concentration of Metolazone can be increased when it is combined with Tropicamide. | Approved |
| Trospium | The serum concentration of Metolazone can be increased when it is combined with Trospium. | Approved |
| Tubocurarine | The serum concentration of Metolazone can be increased when it is combined with Tubocurarine. | Approved |
| Udenafil | Udenafil may increase the antihypertensive activities of Metolazone. | Approved, Investigational |
| Umeclidinium | The serum concentration of Metolazone can be increased when it is combined with Umeclidinium. | Approved |
| Unoprostone | Metolazone may increase the hypotensive activities of Unoprostone. | Approved |
| Valdecoxib | The therapeutic efficacy of Metolazone can be decreased when used in combination with Valdecoxib. | Investigational, Withdrawn |
| Valsartan | The risk or severity of adverse effects can be increased when Valsartan is combined with Metolazone. | Approved, Investigational |
| Vardenafil | Vardenafil may increase the antihypertensive activities of Metolazone. | Approved |
| Vecuronium | The serum concentration of Metolazone can be increased when it is combined with Vecuronium. | Approved |
| Venlafaxine | Venlafaxine may increase the hyponatremic activities of Metolazone. | Approved |
| Verapamil | The risk or severity of adverse effects can be increased when Metolazone is combined with Verapamil. | Approved |
| Vilanterol | Vilanterol may increase the hypokalemic activities of Metolazone. | Approved |
| Vildagliptin | The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Metolazone. | Approved, Investigational |
| Vinpocetine | Metolazone may increase the hypotensive activities of Vinpocetine. | Investigational |
| Voglibose | The therapeutic efficacy of Voglibose can be decreased when used in combination with Metolazone. | Approved, Investigational |
| Xylometazoline | Metolazone may increase the hypotensive activities of Xylometazoline. | Approved |
| Yohimbine | Yohimbine may decrease the antihypertensive activities of Metolazone. | Approved, Vet Approved |
| Zaltoprofen | The therapeutic efficacy of Metolazone can be decreased when used in combination with Zaltoprofen. | Approved |
| Zileuton | The therapeutic efficacy of Metolazone can be decreased when used in combination with Zileuton. | Approved, Investigational, Withdrawn |
| Zimelidine | Zimelidine may increase the hyponatremic activities of Metolazone. | Withdrawn |
| Zomepirac | The therapeutic efficacy of Metolazone can be decreased when used in combination with Zomepirac. | Withdrawn |
